Brukinsa (zanubrutinib) — CareFirst (Caremark)

Initial criteria

• Used as subsequent therapy for members who have received an anti-CD20–based regimen (e.g., rituximab or obinutuzumab).

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months